Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy

Fineline Cube Jan 4, 2024

Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the...

Company Deals

GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies

Fineline Cube Jan 4, 2024

GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...

Company Drug

Sino Biopharmaceutical Ltd Secures Exclusive Rights for Generic Everolimus in China

Fineline Cube Jan 4, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...

Company Deals

Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic

Fineline Cube Jan 4, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...

Company Deals

Bio-Thera Solutions Grants Macter International Exclusive Rights to Avzivi in Pakistan and Afghanistan

Fineline Cube Jan 4, 2024

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement...

Company Deals

Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH

Fineline Cube Jan 4, 2024

Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...

Company Drug

Sciwind Biosciences’ Ecnolgutide Shows Promising Phase III Results in Type 2 Diabetes Treatment

Fineline Cube Jan 4, 2024

Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III...

Company Deals

JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China

Fineline Cube Jan 3, 2024

JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...

Company Drug

InventisBio’s KRAS G12C Inhibitor Garsorasib NDA Accepted for Review by China’s NMPA

Fineline Cube Jan 3, 2024

InventisBio (Shanghai) Co., Ltd (SHA: 688382), a China-based pharmaceutical company, has announced that the New...

Company Deals

Frontage Laboratories Expands European Footprint with Acquisition of Accelera’s DMPK Businesses

Fineline Cube Jan 3, 2024

Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou,...

Company Drug

AstraZeneca and Sanofi’s RSV Prevention Drug Beyfortus Approved by China’s NMPA

Fineline Cube Jan 3, 2024

AstraZeneca (AZ, NASDAQ: AZN) and Sanofi (NASDAQ: SNY), co-development partners in the pharmaceutical industry, have...

Company Deals

China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease

Fineline Cube Jan 3, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...

Company Drug

Ascletis Pharma’s ASC41 Shows Promising Results in Phase II NASH Study

Fineline Cube Jan 3, 2024

Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Approval for NSCLC Perioperative Treatment

Fineline Cube Jan 3, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Drug

Roche’s Phesgo and Faricimab Receive NMPA Approvals for Breast Cancer and nAM

Fineline Cube Jan 3, 2024

The National Medical Products Administration (NMPA) has granted separate approvals for two distinct drugs from...

Company Deals

WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services

Fineline Cube Jan 3, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

BeiGene’s Tislelizumab Secures 12th Indication Approval in China for HCC First-Line Treatment

Fineline Cube Jan 3, 2024

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...

Company Drug

BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments

Fineline Cube Jan 3, 2024

The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...

Company Deals

Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization

Fineline Cube Jan 3, 2024

Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...

Company Deals

Orient Gene Biotech to Acquire Hangzhou Laihe Biotech, Expanding POCT and AI in Healthcare

Fineline Cube Jan 3, 2024

Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to...

Posts pagination

1 … 464 465 466 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.